Late-Onset Retinal Degeneration Overview

Save information for later
Sign Up

Learn About Late-Onset Retinal Degeneration

What is the definition of Late-Onset Retinal Degeneration?
Late-onset retinal degeneration is an inherited retinal dystrophy characterized by delayed dark adaptation and nyctalopia and drusen deposits presenting in adulthood, followed by cone and rod degeneration that presents in the sixth decade of life, which leads to central vision loss. Anterior segment features such as peripupillary iris transillumination defects and abnormally long anterior zonular insertions are also observed. Choroidal neovascularization and glaucoma may occur in the late stages of the disease.
What are the alternative names for Late-Onset Retinal Degeneration?
  • Late-onset retinal degeneration
  • Autosomal dominant late-onset retinal degeneration
  • LORD
  • Pigmentary retinopathy
  • Retinal degeneration, late-onset, autosomal dominant
Who are the top Late-Onset Retinal Degeneration Local Doctors?
Glenn J. Jaffe
Elite in Late-Onset Retinal Degeneration
Dr. Glenn J. Jaffe
Ophthalmology | General Surgery
Elite in Late-Onset Retinal Degeneration
Dr. Glenn J. Jaffe
Ophthalmology | General Surgery

Duke Eye Center

2351 Erwin Rd, 
Durham, NC 
919-681-3937
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Glenn Jaffe is an Ophthalmologist and a General Surgeon in Durham, North Carolina. Dr. Jaffe is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Trabeculectomy. Dr. Jaffe is currently accepting new patients.

Richard F. Spaide
Elite in Late-Onset Retinal Degeneration
Dr. Richard F. Spaide
Ophthalmology
Elite in Late-Onset Retinal Degeneration
Dr. Richard F. Spaide
Ophthalmology

Vitreous Retina Macula Consultants Of New York(Downtown)

110 Lafayette St, Suite 502, 
New York, NY 
212-234-3367
Languages Spoken:
English
See accepted insurances

Richard Spaide is an Ophthalmologist in New York, New York. Dr. Spaide is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Central Serous Chorioretinopathy, and Vitrectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Dilraj S. Grewal
Elite in Late-Onset Retinal Degeneration
Dr. Dilraj S. Grewal
Ophthalmology | General Surgery
Elite in Late-Onset Retinal Degeneration
Dr. Dilraj S. Grewal
Ophthalmology | General Surgery

Duke Eye Center

2351 Erwin Rd, 
Durham, NC 
919-681-3937
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dilraj Grewal is an Ophthalmologist and a General Surgeon in Durham, North Carolina. Dr. Grewal is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Uveitis, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Cataract Removal, and Vitrectomy. Dr. Grewal is currently accepting new patients.

View All Doctors
What are the latest Late-Onset Retinal Degeneration Clinical Trials?
A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients With Either Autosomal-Dominant BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD]) or Autosomal-Recessive Bestrophinopathy (ARB)
A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients With Either Autosomal-Dominant BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD]) or Autosomal-Recessive Bestrophinopathy (ARB)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2

Summary: The goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1. The main questions it aims to answer are: Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the treatment eye), for 5 years post-injection, in participants with BVMD or ARB. A second question it aims to answer is iden...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: Neovascular age-related macular degeneration (nAMD), also known as wet AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) i...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center